PharmaShots

MAY 29, 2023

Shots: The companies collaborated to discover & develop novel therapies for patients with neurodegenerative diseases incl. Parkinson's disease The collaboration will combine companies’ expertise and resources in developing NurrOn's ATH-399A & other compounds targeting Nurr1 for neurodegenerative disorders.

Compounding 40

Compounding 40

Pharmacy Times

NOVEMBER 23, 2022

IPX203 is a novel, oral formulation of carbidopa/levodopa extended-release capsules.

FDA 123

FDA 123

PharmExec

FEBRUARY 22, 2024

Early-stage trial results indicate that NLRP3 inflammasome inhibitors were able to achieve nearly the same weight loss as Wegovy while also reducing inflammatory biomarkers linked to heart disease.

52

52

STAT

OCTOBER 24, 2023

But now, after nearly a decade of development, the Apple Watch is being leveraged on an entirely new health frontier: Parkinson’s disease, the degenerative brain disorder that affects more than a half million Americans. Continue to STAT+ to read the full story…

People Management 141

People Management 141

STAT

JANUARY 11, 2024

Rune Labs, maker of an Apple Watch app that can track symptoms related to Parkinson’s disease, announced Thursday $12 million in funding led by Nexus NeuroTech, a new venture capital fund focused on brain disorders. Rune also works with drug companies developing treatments for the disease.

95

95

Fierce Pharma

APRIL 2, 2024

After years of struggling with hurdles such as generic competition and significantly lower-than-expected sales of its top meds, Acorda Therapeutics is hanging up the gloves with a $185 million deal | Merz Therapeutics, in a "stalking horse bid," agreed to pick up Acorda's Parkinson's disease med Inbrija and multiple sclerosis drug (..)

108

108

pharmaphorum

JANUARY 31, 2024

In this exclusive interview, Gene Kinney, CEO of Prothena, discusses the latest developments in the field of neurodegenerative diseases such as Alzheimer's and Parkinson's. Gain insights and advancements being made in the treatment of these conditions.

120

120

STAT

FEBRUARY 29, 2024

The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.  In Parkinson’s, the idea is that these cells would replace damaged neurons.

113

113

STAT

MAY 1, 2024

Efforts to treat other diseases, such as cancer and Parkinson’s , with mitochondrial transplantation have met with mixed success. Atherosclerosis can also lead to peripheral artery disease from reduced blood flow in the arms or legs.

Hospitals 101

Hospitals 101

Pharmaceutical Technology

FEBRUARY 28, 2024

Amneal has signed an agreement with Zambon Biotech for IPX203 for the treatment of Parkinson's disease (PD) in certain regions.

98

98

STAT

AUGUST 25, 2023

doctors have discovered a genetic variant that increases the risk of Parkinson’s disease in people of African and mixed-African descent and is not seen in those with European ancestry, a finding that could improve treatment of the movement disorder in a vastly underserved population. A group of Nigerian, British, and U.S.

96

96

Pharmaceutical Technology

APRIL 30, 2024

Discover how Ionis Pharmaceuticals' patent for modified oligonucleotides offers hope in treating Parkinson's disease by reducing LRRK2 levels and alleviating symptoms. Explore the groundbreaking methods and compounds outlined in this comprehensive framework.

Compounding 52

Compounding 52

pharmaphorum

JANUARY 25, 2024

NICE firms up guidance backing NHS use of five digital health wearables for remote monitoring of Parkinson's disease patients

108

108

STAT

OCTOBER 19, 2023

Fox was diagnosed with Parkinson’s disease at age 29, his clearest symptom was a small one — his pinky finger was twitching. When Michael J. But even by that stage, 70% to 80% of a patient’s dopamine-producing cells are already gone, Fox said. “What happens in that time, that shadowy place?”

134

134

Outsourcing Pharma

JUNE 5, 2023

Encouraging clinical data has been released by Biovie, a company developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.

87

87

Pharmacy Times

JANUARY 11, 2023

Analysis indicates that Acadia Pharmaceuticals Inc’s pimavanserin is the only FDA-approved medication for the treatment of delusions and hallucinations associated with PDP.

FDA 65

FDA 65

PharmExec

APRIL 8, 2024

According to the letter, the FDA believes that the investigational apomorphine infusion device is not ready for approval in its current form.

FDA 52

FDA 52

STAT

MARCH 11, 2024

The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.   The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia.

108

108

STAT

JANUARY 25, 2024

Damian here with the plight of the venture capitalist, an idea for Gilead Sciences, and the latest in the quest to find potent treatments for Parkinson’s disease. Good morning, everyone. Read the rest…

91

91

STAT

APRIL 18, 2024

Cerevel Therapeutics, a neuroscience biotech that AbbVie is acquiring, reported that its Parkinson’s disease drug improved motor symptom control as an add-on therapy in a late-stage trial , STAT writes. When China relations.  When AbbVie announced its $8.7

92

92

STAT

APRIL 17, 2024

Sage Therapeutics will stop development of its experimental drug to treat Parkinson’s disease after the treatment failed a mid-stage study, sending the company’s shares tumbling 36% before stock trading opened , Reuters reports.

Insurance Coverage 77

Insurance Coverage FDA Insurance 77

pharmaphorum

DECEMBER 2, 2021

Novartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first oral, disease-modifying drug for the disease – if it can avoid the fate of earlier drugs in the class. The post Novartis takes aim at risky Parkinson’s target with $1.5bn UCB deal appeared first on.

Compounding 106

Compounding 106

PharmaVoice

JULY 24, 2023

Amid a wave of neuro R&D, scientists are taking an Alzheimer’s-like approach to developing the first disease-modifying treatments for Parkinson’s.

98

98

Pharmaceutical Technology

APRIL 4, 2024

Discover Chiesi Farmaceutici's innovative patent for a specialized pharmaceutical formulation aimed at enhancing drug delivery efficiency for Parkinson's disease treatment. Learn about the unique composition and processes involved in this groundbreaking intraduodenal administration solution.

52

52

Pharmaceutical Technology

MARCH 22, 2024

is revolutionizing Parkinson's disease treatment with RNA molecules and CRISPR technology. Discover how AnGes Inc. Learn about their patent for precise genetic modifications.

52

52

European Pharmaceutical Review

DECEMBER 8, 2023

Cerevel’s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease, and mood disorders. Emraclidine is a positive allosteric modulator (PAM) of the muscarinic M4 receptor. AbbVie also agreed a $10.1

FDA 94

FDA 94

STAT

MAY 1, 2024

Early onset Parkinson’s disease, diagnosed at age 49, had disabled him, ended his bartending career, and led him to consider suicide. NEW YORK — By the time Peter Bauman considered deep brain stimulation, he was desperate.

Documentation 127

Documentation FDA Nursing Homes 127

STAT

APRIL 12, 2023

Fox was sitting in his Upper East Side office surrounded by Emmys and an Oscar — one he received not for his acting but for his Parkinson’s philanthropy. (“Humanitarian stuff,” he said nonchalantly.) He wore blue trousers and a T-shirt, and Adidas sneakers with no socks. Read the rest…

103

103

STAT

APRIL 4, 2024

… The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, such as mental health disorders, Alzheimer’s, and even, as new study results suggest — Parkinson’s disease , STAT writes. In

83

83

STAT

FEBRUARY 23, 2024

meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.

77

77

Pharmaceutical Technology

JANUARY 22, 2024

Stem Cell Therapy for Parkinson's Disease is under clinical development by Hebei Newtherapy BIo-Pharma Technology and currently in Phase I for Parkinson's Disease.

40

40

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. The post BioArctic left in the cold as AbbVie abandons Parkinson’s pact appeared first on.

91

91

Outsourcing Pharma

FEBRUARY 14, 2023

Series B financing of $51 million (â47 million) has closed a funding round for a Parkinsonâs Disease drug advancing to a phase 2 clinical study.

52

52

PharmaVoice

JANUARY 9, 2023

How the IRLAB Therapeutics CEO is guiding the company in its development of potentially groundbreaking Parkinson’s disease treatments.

98

98

pharmaphorum

JANUARY 13, 2022

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio in a deal that could be worth more than $1 billion. Despite the interest, there have already been some failures in the alpha-synuclein category.

Immunization 94

Immunization Vaccines 94

European Pharmaceutical Review

AUGUST 24, 2023

A new drug formulation of a protein kinase inhibitor therapeutic designed to modify the course of Parkinson’s diseas e has been developed. Inhibikase Therapeutics submitted two Investigational New Drug (IND) applications in February 2019 to start the clinical development in multiple classes of Parkinson’s disease patients.

89

89

pharmaphorum

JUNE 7, 2022

Biogen has added a preclinical-stage drug candidate for Parkinson’s disease via a $722.5 In a statement , Biogen said that AL01811 is designed to target dysfunction in lysosomes – organelles which play a vital role in cell function by breaking down excess or worn-out cell parts and can be impaired in Parkinson’s.

Compounding 73

Compounding 73